Randomized	O
,	O
open	O
label	O
,	O
prospective	O
study	O
on	O
the	O
effect	O
of	O
zoledronic	O
acid	O
on	O
the	O
prevention	O
of	O
bone	B-Cancer
metastases	I-Cancer
in	O
patients	O
with	O
recurrent	O
solid	B-Cancer
tumors	I-Cancer
that	O
did	O
not	O
present	O
with	O
bone	B-Cancer
metastases	I-Cancer
at	O
baseline	O
.	O

OBJECTIVES	O
:	O
Bisphosphonates	O
have	O
been	O
used	O
successfully	O
in	O
the	O
treatment	O
of	O
hypercalcemia	O
and	O
to	O
reduce	O
skeletal	B-Anatomical_system
-	O
related	O
complications	O
of	O
bone	B-Cancer
metastases	I-Cancer
.	O

Recent	O
in	O
vitro	O
and	O
in	O
vivo	O
evidence	O
suggest	O
that	O
they	O
may	O
also	O
have	O
direct	O
antitumor	B-Cancer
effects	O
via	O
induction	O
of	O
apoptosis	O
,	O
inhibition	O
of	O
the	O
invasive	O
potential	O
of	O
tumor	B-Cell
cell	I-Cell
lines	I-Cell
in	O
vitro	O
,	O
inhibition	O
of	O
angiogenesis	O
,	O
and	O
reduction	O
in	O
tumor	B-Cancer
growth	O
indirectly	O
via	O
effects	O
on	O
accessory	B-Cell
cells	I-Cell
.	O

This	O
is	O
a	O
randomized	O
,	O
open	O
label	O
,	O
prospective	O
study	O
that	O
examined	O
the	O
effect	O
of	O
preventive	O
zoledronic	O
acid	O
treatment	O
on	O
the	O
development	O
of	O
bone	B-Cancer
metastases	I-Cancer
in	O
patients	O
with	O
recurrent	O
solid	B-Cancer
tumors	I-Cancer
,	O
without	O
bone	B-Cancer
metastases	I-Cancer
at	O
the	O
time	O
of	O
randomization	O
.	O

METHODS	O
:	O
Forty	O
patients	O
with	O
recurrent	O
or	O
metastatic	B-Cancer
advanced	I-Cancer
cancer	I-Cancer
,	O
without	O
bone	B-Cancer
metastases	I-Cancer
,	O
were	O
randomized	O
into	O
the	O
trial	O
to	O
either	O
receive	O
zoledronic	O
acid	O
or	O
no	O
treatment	O
.	O

Patients	O
were	O
followed	O
up	O
until	O
bone	B-Cancer
metastases	I-Cancer
were	O
established	O
.	O

RESULTS	O
:	O
The	O
percentage	O
of	O
patients	O
being	O
bone	B-Cancer
metastases	I-Cancer
free	O
at	O
12	O
mo	O
was	O
60	O
%	O
in	O
the	O
zoledronic	O
acid	O
and	O
10	O
%	O
in	O
the	O
control	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
0005	O
)	O
,	O
while	O
the	O
percentages	O
at	O
18	O
mo	O
were	O
20	O
%	O
and	O
5	O
%	O
respectively	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
have	O
shown	O
that	O
bisphosphonates	O
as	O
adjuvant	O
treatment	O
might	O
be	O
useful	O
for	O
the	O
prevention	O
of	O
bone	B-Cancer
metastases	I-Cancer
;	O
however	O
,	O
there	O
is	O
need	O
for	O
blinded	O
randomized	O
data	O
before	O
such	O
an	O
approach	O
would	O
be	O
confirmed	O
.	O

In	O
the	O
meantime	O
preventive	O
use	O
of	O
bisphosphonates	O
in	O
patients	O
without	O
any	O
bone	B-Cancer
metastases	I-Cancer
should	O
not	O
be	O
used	O
outside	O
the	O
scope	O
of	O
a	O
clinical	O
trial	O
.	O

